– Full year 2019 net revenues increased by 29% and operating loss decreased by $33M –
– Neos RxConnect rapidly expanded with ~500 pharmacies in network at year-end –
– NT0502 Phase 1 ascending dose trial initiation planned in 2H20 following top-line PK data –
– Company to host conference call today at 8:30am ET –
DALLAS and FORT WORTH, Texas, March 13, 2020 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous system-focused products, today reported financial results for the fourth quarter and fiscal year ended December 31, 2019 and provided a business update.
“We made tremendous strides in 2019, following the reset of our commercial strategy for our ADHD portfolio, which resulted in an improvement to the financial foundation of the company. In particular, we realized a 29% increase in net revenues for the full year of 2019 compared to 2018 and through our focus on operational productivity and expense management, we reduced our operating loss by approximately $33 million compared to 2018. During the year, we established and rapidly grew our proprietary Neos RxConnect patient support program to approximately 500 pharmacies. As we look forward, we are confident in the outlook for 2020 and beyond,” said Jerry McLaughlin, president and chief executive officer. “We are also extremely pleased to now have top-line results from the NT0502 Phase 1 pilot pharmacokinetic study, and we plan to initiate an ascending dose study in the second half of the year. We believe NT0502 has the potential to address a significantly underserved patient population of individuals struggling with chronic sialorrhea, otherwise known as excessive drooling, across numerous debilitating CNS disorders.”
ADHD Commercial Franchise
- Increased net revenue per pack by over 30 percent: Neos reported growth in net product sales and net revenue per pack for its two core commercial attention deficit hyperactivity disorder (ADHD) products, Adzenys XR-ODT® and Cotempla XR-ODT®, for the three months ended December 31, 2019 compared to the same period in 2018.
| Net Revenue per Pack | ||||||
| Q4 2019 | Q4 2018 | % Change | ||||
| Adzenys XR-ODT | $128 | $97 | 32% | |||
| Cotempla XR-ODT | $126 | $95 | 33% | |||
- Strong growth in Neos RxConnect patient support program: During the fourth quarter of 2019, the company substantially expanded the number of participating pharmacies in the Neos RxConnect network to approximately 500 pharmacies, including one regional pharmacy chain, as of December 31, 2019. In mid-March, the company added a second regional pharmacy chain with approximately 250 pharmacies to the network, and it remains in active discussions with a number of other regional pharmacies strategically aligned in Neos territories.
- Planned 2Q 2020 commercial launch of ADHD portfolio in Puerto Rico: Neos recently entered into an agreement with a third-party to commercialize Neos’ ADHD portfolio in Puerto Rico. The commercial launch is anticipated to occur in the second quarter of 2020.
Advancing Clinical Pipeline
- Phase 1 pilot pharmacokinetic top-line data for NT0502: The company has completed a Phase 1 pilot study evaluating the pharmacokinetic profile of multiple formulations of NT0502 in 30 healthy adult volunteers. The top-line data confirms a formulation for further clinical development.
- NT0502 Phase 1 ascending dose trial to begin in second half of 2020: The company plans to initiate a Phase 1 clinical trial of NT0502 in the second half of 2020. The multi-part study will include single ascending and multiple ascending dose cohorts.
Financial Highlights and Select Financial Results
- For the fourth quarter of 2019, net loss narrowed to $3.5 million, down from $9.3 million in the fourth quarter of 2018, reflecting the evolution of the commercial strategy and the company’s focus on both operational productivity and expense management.
- Total product revenues were $16.8 million for the three months ended December 31, 2019, compared to $15.4 million for the same period in 2018. For the fiscal year ended December 31, 2019, total product revenues were $64.6 million, compared to $50.0 million for the fiscal year ended December 31, 2018.
| Fourth Quarter | Fiscal Year | ||||||||
| 2019 | 2018 | % Change | 2019 | 2018 | % Change | ||||
| Adzenys XR-ODT | $8.5MM | $8.1MM | 4.9 | % | $31.2MM | $26.6MM | 173 | % | |
| Cotempla XR-ODT | $6.1MM | $6.1MM | 0 | % | $25.6MM | $19.0MM | 34.7 | % | |
| Adzenys ER | $0.3MM | * | * | $0.8MM | * | * | |||
| Generic Tussionex | $1.9MM | $1.4MM | 35.7 | % | $7.0MM | $4.3MM | 62.8 | % | |
| Total | $16.8MM | $15.4MM | 9.1 | % | $64.6MM | $50.0MM | 29.2 | % | |
| * Adzenys ER revenue was negligible in Q4 and fiscal year 2018. | |||||||||
- Gross profit was $9.7 million for the three months ended December 31, 2019, compared to $7.6 million for the same period in 2018. For the fiscal year ended December 31, 2019, gross profit was $39.5 million, compared to $23.1 million for the fiscal year ended December 31, 2018.
- Research and development expenses were $1.8 million for the three months ended December 31, 2019, compared to $2.4 million for the same period in 2018. For the fiscal year ended December 31, 2019, research and development expenses were $8.6 million, compared to $8.5 million for the fiscal year ended December 31, 2018.
- Selling and marketing expenses were $6.7 million for the three months ended December 31, 2019, compared to $9.1 million for the same period in 2018. For the fiscal year ended December 31, 2019, selling and marketing expenses were $28.1 million, compared to $44.1 million for the fiscal year ended December 31, 2018.
- General and administrative expenses were $2.9 million for the three months ended December 31, 2019, compared to $3.3 million for the same period in 2018. For the fiscal year ended December 31, 2019, general and administrative expenses were $13.2 million, compared to $13.9 million for the fiscal year ended December 31, 2018.
- Net loss for the three months ended December 31, 2019 was $3.5 million, or $0.07 per share, compared to a net loss of $9.3 million, or $0.23 per share, for the same period in 2018. For the fiscal year ended December 31, 2019, net loss was $16.9 million, or $0.34 per share, compared to a net loss of $51.7 million, or $1.60 per share for the fiscal year ended December 31, 2018.
- At December 31, 2019, the company held $24.9 million in cash and cash equivalents and short-term investments.
Conference Call Details
Neos management will host a conference call and live audio webcast to discuss results and provide a Company update at 8:30 a.m. ET today. The live call may be accessed by dialing (877) 388-8985 for domestic calls, or +1 (562) 912-2654 for international callers, and referencing conference ID number 5454889. A live audio webcast for the conference call will be available on the Investor Relations page of the Company’s website at http://investors.neostx.com/. Following the conclusion of the call, the webcast will be available for replay for 30 days.
About Neos Therapeutics
Neos Therapeutics, Inc. (NASDAQ: NEOS) is a commercial-stage pharmaceutical company utilizing its novel microparticle delivery technology to develop and manufacture central nervous system (CNS)-focused products. Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING), Cotempla XR-ODT® (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING), and Adzenys-ER® (amphetamine) extended-release oral suspension (see Full Prescribing Information, including Boxed WARNING), all for the treatment of ADHD, are three approved products utilizing the Company’s novel microparticle delivery technology. Additional information about Neos is available at www.neostx.com.
Forward-Looking Statements
Any statements in this press release about future expectations, plans and prospects for the Company, including statements about the Company’s strategy, future operations, commercial products, clinical development of its therapeutic candidates, plans for potential future product candidates, financial condition and outlook, and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “suggest,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the net sales, profitability, and growth of the Company’s commercial products, including the Company’s confidence in the outlook for 2020 and beyond, the Company’s future expansion of the Neos RxConnect network and the expected launch of the Company’s ADHD products in Puerto Rico; the status, timing, costs, results and interpretation of the Company’s clinical trials or any future trials, including whether the Company will initiate a Phase 1 ascending dose study of NT0502 in the second half of 2020 and whether NT0502 has the potential to address a significantly underserved patient population; the uncertainties inherent in conducting clinical trials, including whether the Phase 1 pilot study of NT0502 confirms a formulation for further clinical development; expectations for regulatory interactions, submissions and approvals; the financial condition and outlook for the Company, including whether the Company will continue to make progress towards its goal of achieving operational profitability; availability of funding sufficient for the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements; uncertainties related to the Company’s intellectual property; other matters that could affect the availability or commercial potential of the Company’s commercial products or therapeutic candidates; and other factors discussed in the Risk Factors set forth in the Company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission (SEC) and in other filings the Company makes with the SEC from time to time. In addition, the forward-looking statements included in this press release represent the Company’s views only as of the date hereof. The Company anticipates that subsequent events and developments may cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, except as may be required by law.
Neos Therapeutics, Inc. and Subsidiaries
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except share and per share data)
(unaudited)
| December 31, | December 31, | |||||||
| 2019 | 2018 | |||||||
| ASSETS | ||||||||
| Current Assets: | ||||||||
| Cash and cash equivalents | $ | 16,830 | $ | 46,478 | ||||
| Short-term investments | 8,064 | — | ||||||
| Accounts receivable, net of allowances for chargebacks and cash discounts of $4,848 and $1,865 at December 31, 2019 and 2018, respectively | 26,563 | 27,801 | ||||||
| Inventories | 11,010 | 10,367 | ||||||
| Prepaid expenses and other current assets | 4,092 | 4,032 | ||||||
| Total current assets | 66,559 | 88,678 | ||||||
| Property and equipment, net | 7,345 | 7,914 | ||||||
| Operating lease right-of-use assets | 3,044 | — | ||||||
| Intangible assets, net | 12,543 | 14,616 | ||||||
| Other assets | 1,382 | 149 | ||||||
| Total assets | $ | 90,873 | $ | 111,357 | ||||
| LIABILITIES AND STOCKHOLDERS' (DEFICIT) EQUITY | ||||||||
| Current Liabilities: | ||||||||
| Accounts payable | $ | 6,650 | $ | 12,730 | ||||
| Accrued expenses | 40,188 | 35,818 | ||||||
| Current portion of operating lease liabilities | 681 | — | ||||||
| Current portion of long-term debt | 15,836 | 8,557 | ||||||
| Total current liabilities | 63,355 | 57,105 | ||||||
| Long-Term Liabilities: | ||||||||
| Long-term debt, net of current portion | 29,099 | 43,217 | ||||||
| Operating lease liabilities | 3,254 | — | ||||||
| Derivative liability | 1,135 | 2,017 | ||||||
| Deferred rent | — | 989 | ||||||
| Other long-term liabilities | 160 | 184 | ||||||
| Total long-term liabilities | 33,648 | 46,407 | ||||||
| Stockholders' (Deficit) Equity: | ||||||||
| Preferred stock, $0.001 par value, 5,000,000 shares authorized, no shares issued or outstanding at December 31, 2019 and 2018 | — | — | ||||||
| Common stock, $0.001 par value, 100,000,000 shares authorized at December 31, 2019 and 2018; 49,766,472 and 49,732,671 shares issued and outstanding, respectively, at December 31, 2019; 49,710,104 and 49,676,303 shares issued and outstanding, respectively, at December 31, 2018 | 50 | 50 | ||||||
| Treasury stock, at cost, 33,801 shares at December 31, 2019 and 2018 | (352 | ) | (352 | ) | ||||
| Additional paid-in capital | 328,056 | 325,130 | ||||||
| Accumulated deficit | (333,885 | ) | (316,983 | ) | ||||
| Accumulated other comprehensive income | 1 | — | ||||||
| Total stockholders' (deficit) equity | (6,130 | ) | 7,845 | |||||
| Total liabilities and stockholders' (deficit) equity | $ | 90,873 | $ | 111,357 | ||||
Neos Therapeutics, Inc. and Subsidiaries
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except share and per share data)
(unaudited)
| Three Months Ended | Year Ended | |||||||||||||||
| December 31, | December 31, | |||||||||||||||
| 2019 | 2018 | 2019 | 2018 | |||||||||||||
| Revenues: | ||||||||||||||||
| Net product sales | $ | 16,832 | $ | 15,393 | $ | 64,649 | $ | 49,988 | ||||||||
| Cost of goods sold | 7,181 | 7,763 | 25,123 | 26,928 | ||||||||||||
| Gross profit | 9,651 | 7,630 | 39,526 | 23,060 | ||||||||||||
| Research and development expenses | 1,825 | 2,399 | 8,582 | 8,508 | ||||||||||||
| Selling and marketing expenses | 6,659 | 9,140 | 28,122 | 44,133 | ||||||||||||
| General and administrative expenses | 2,882 | 3,327 | 13,237 | 13,915 | ||||||||||||
| Loss from operations | (1,715 | ) | (7,236 | ) | (10,415 | ) | (43,496 | ) | ||||||||
| Interest expense | (2,038 | ) | (2,262 | ) | (8,009 | ) | (8,974 | ) | ||||||||
| Other income, net | 276 | 161 | 1,533 | 795 | ||||||||||||
| Loss before income taxes | (3,477 | ) | (9,337 | ) | (16,891 | ) | (51,675 | ) | ||||||||
| Income tax expense (benefit) | 11 | — | 11 | — | ||||||||||||
| Net loss | $ | (3,488 | ) | $ | (9,337 | ) | $ | (16,902 | ) | $ | (51,675 | ) | ||||
| Weighted average common shares outstanding used to compute net loss per share, basic and diluted | 49,732,654 | 41,415,358 | 49,723,772 | 32,288,555 | ||||||||||||
| Net loss per share of common stock, basic and diluted | $ | (0.07 | ) | $ | (0.23 | ) | $ | (0.34 | ) | $ | (1.60 | ) | ||||
Contacts:
Richard Eisenstadt
Chief Financial Officer
Neos Therapeutics, Inc.
(972) 408‑1389
reisenstadt@neostx.com
Sarah McCabe
Stern Investor Relations, Inc.
(212) 362‑1200
sarah.mccabe@sternir.com